Abstracts tagged "Cardiovascular disease"

Abstract Number: 2932 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Deep Vein Thrombosis and Pulmonary Embolism in Sjögren’s Syndrome: A General Population-Based Cohort Study
Marko Yurkovich¹, Hyon K. Choi², Eric C. Sayre³, Kamran Shojania⁴ and J. Antonio Avina-Zubieta⁵, ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Boston University School of Medicine, Boston, MA, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: There is limited data available on the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in Sjögren's Syndrome (SjS). We estimated the…
Abstract Number: 2098 • 2014 ACR/ARHP Annual Meeting
Genetic Variants of the NLRP3 Inflammasome Are Associated with Stroke in Patients with Rheumatoid Arthritis
Alf Kastbom¹, Lisbeth Ärlestig² and Solbritt M. Rantapää-Dahlqvist³, ¹Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ²Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden
Background/Purpose Inflammasomes are intra-cellular protein complexes important for the production of pro-inflammatory cytokines such as interleukin-(IL-)1β and IL-18. Cardiovascular disease is over-represented in patients with…
Abstract Number: 1410 • 2014 ACR/ARHP Annual Meeting
Low Rates of Cardiovascular Risk Factor Modification Among High-Risk Rheumatoid Arthritis Patients: Barrier to Cardiovascular Prevention Strategies?
Kimberly P. Liang¹, Rohit Aggarwal², Juan (June) Feng³, Jason Lyons³, Heather Eng³, Stephen R. Wisniewski³, Melissa Saul⁴, Douglas P. Landsittel⁵, Douglas W. Chew¹, Aryan Aiyer⁶ and Larry W. Moreland⁷, ¹Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴Biomedical Informatics, University of Pittsburgh, School of Medicine, Pittsburgh, PA, ⁵Medicine, Biostatistics and Clinical and Translational Science, University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, ⁶Department of Medicine, Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Despite higher risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA), systematic cardiovascular (CV) prevention strategies are lacking. Recent guidelines for CV risk…
Abstract Number: 945 • 2014 ACR/ARHP Annual Meeting
Disease Remission Reduces Risk of Heart Failure in Rheumatoid Arthritis Patients Independent of Treatment Strategy
Thomas Schau¹, Michael Gottwald², Christian Butter¹ and Michael Zaenker³, ¹Cardiology Dept., Immanuel Klinikum Bernau Heart Center Brandenburg, Bernau, Germany, ²Internal Med. Dept., Immanuel Klinikum Bernau, Rheumatology Center Northern Brandenburg, Bernau, Germany, ³Immanuel Klinikum Bernau, Rheumatology Center Northern Brandenburg, Bernau, Germany
Background/Purpose Risk of heart failure (HF) is increased in patients with RA, however there is great variance in reported prevalence rates due to different diagnostic…
Abstract Number: 355 • 2014 ACR/ARHP Annual Meeting
Increased Left Ventricular Mass Index and Decreased Ejection Fraction Are Associated with Disease Activity in Rheumatoid Arthritis Patients without Cardiac Symptoms; Comparison Between Non-Biologic and Biologic Dmards Treatment Groups, Using a Cardiac Magnetic Resonance Imaging
Hitomi Kobayashi¹, Yasuyuki Kobayashi², Atsuma Nishiwaki³, Hirotake Inomata¹, Noboru Kitamura¹, Hidetake Shiraiwa³, Takamasa Nozaki³, Natsumi Ikumi⁴ and Masami Takei⁵, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, ³Nihon University School of Medicine, Tokyo, Japan, ⁴Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁵Dept of Med Rheumatology, Nihon University School of Medicine, Itabashi Tokyo, Japan
Background/Purpose Patients with rheumatoid arthritis (RA) experience an excess risk of congestive heart failure (CHF), but effects of disease-modifying anti-rheumatic drugs (DMARDs) on cardiac structure…
Abstract Number: 2889 • 2014 ACR/ARHP Annual Meeting
The Association Between Changes in Inflammation and High Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis
K P Liao¹, Martin Playford², Michelle A. Frits³, Christine K. Iannaccone⁴, Jonathan S. Coblyn¹, Michael E. Weinblatt⁵, Nancy A. Shadick⁶ and Nehal N. Mehta⁷, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²National Heart, Blood, and Lung Institute, Bethesda, MD, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital/Harvard University, Cambridge, MA, ⁷Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: High density lipoprotein (HDL) cholesterol efflux capacity measures the functional ability of HDL to remove cholesterol from atherosclerotic plaque. Low HDL efflux capacity is…
Abstract Number: 2084 • 2014 ACR/ARHP Annual Meeting
Are Genetic Markers Associated with Myocardial Infarction in Patients with Early Rheumatoid Arthritis?
Lisbeth Ärlestig¹, Petros Zamout², Lena Innala³, Eva Freyhult⁴, Solveig Wållberg Jonsson² and Solbritt Rantapää-Dahlqvist², ¹Public Health & Clinical Medicine/Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Rheumatology, Sweden, Umea, Sweden, ²Public Health & Clinical Medicine/Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Rheumatology, Sweden, Umeå, Sweden, ³Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Rheumatology, Sweden, Umeå, Sweden, ⁴Bioinformatics Infrastructure for Life Sciences, Uppsala, Sweden
Background/Purpose Cardiovascular disease (CVD) are increased in patients with rheumatoid arthritis (RA). Traditional as well as disease related risk factors seem to contribute to the…
Abstract Number: 1405 • 2014 ACR/ARHP Annual Meeting
Five-Year Changes in Myocardial Structure and Function in Patients with Rheumatoid Arthritis
John M. Davis III¹, Grace Lin², Jae Oh³, Cynthia S. Crowson⁴, Terry M. Therneau⁵, Eric L. Matteson¹ and Sherine E. Gabriel⁶, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Cardiology, Mayo Clinic, Rochester, MN, ³Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) suffer an increased risk of heart failure not explained by traditional cardiovascular risk factors. Previously, we have shown…
Abstract Number: 898 • 2014 ACR/ARHP Annual Meeting
Traditional Cardiovascular Risk-Factor Management in Patients with Rheumatoid Arthritis Compared with Matched Non-Rheumatoid Arthritis Patients in a US Managed Care Setting
J An¹, K Reynolds², E Alemao³, H Kawabata³, D H Solomon⁴, K P Liao⁵ and T C Cheetham², ¹Western University of Health Sciences, Pomona, CA, ²Kaiser Permanente Southern California, Pasadena, CA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Studies have suggested suboptimal care of traditional cardiovascular risk factors (CRF) in patients (pts) with RA as a reason for elevated CV risk compared…
Abstract Number: 354 • 2014 ACR/ARHP Annual Meeting
Increased Vascular Wall Inflammation in Patients with Active Rheumatoid Arthritis As Measured By an 18F-FDG-PET/CT Scan
Rabia Agca^1,2, Alper M. van Sijl^2,3, Yvo M. Smulders⁴, Alexandre E. Voskuyl⁵, Connie J. van der Laken⁶, Ronald Boellaard⁷, Karel-Jan D.F. Lensen⁸ and Michael T. Nurmohamed^1,2, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²VU University Medical Center, Amsterdam, Netherlands, ³[email protected], Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁴Internal Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁵Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁷Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁸Department of Internal Medicine, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose : Patients with rheumatoid arthritis (RA) have an elevated risk of developing cardiovascular disease (CVD). Like active RA, atherosclerosis is an inflammatory process. There…
Abstract Number: 2829 • 2014 ACR/ARHP Annual Meeting
Spondyloarthritis Is Associated with Increased Cardiovascular and Cerebrovascular Mortality
Nigil Haroon¹, Nisha Nigil Haroon², Ping Li³, Michael Paterson³ and Robert D. Inman⁴, ¹Toronto Western Research Institute, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose OnSpA is a population-based study of spondyloarthritis (SpA) based on a provincial population of over 13 million. Patients with SpA are thought to be…
Abstract Number: 1913 • 2014 ACR/ARHP Annual Meeting
Rosuvastatin Induced Carotid Plaque Regression in Patients with Inflammatory Joint Diseases
Silvia Rollefstad¹, Eirik Ikdahl¹, Jonny Hisdal², Inge C. Olsen³, Ingar Holme⁴, Hilde Berner Hammer⁵, Knut T. Smerud⁶, G Kitas⁷, Terje R. Pedersen⁸, Tore K. Kvien⁹ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Vascular Investigations, Uslo University Hospital-Aker, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of biostatistics, epidemiology and health economics, Oslo University Hospital, Oslo, Norway, ⁵Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, ⁶Smerud Medical Research International AS, Oslo, Norway, ⁷The Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, ⁸Faculty of Medicine, University of Oslo, Oslo, Norway, ⁹PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose Patients with rheumatoid arthritis (RA) and carotid artery plaques (CP) have increased risk of acute coronary syndromes. Statin treatment with low density lipoprotein cholesterol…
Abstract Number: 1390 • 2014 ACR/ARHP Annual Meeting
Heterogeneity in Cardiovascular Risk Factors, Event Rates and RA Disease Characteristics Among Patients with Rheumatoid Arthritis Across 10 Countries – Implications for CV Risk Assessment
Atacc-RA Collaborative Group, Division of Rheumatology, Mayo Clinic, Rochester, MN; Diakonhjemmet hospital, Oslo, Norway; Dudley Group NHS Foundation Trust, West Midlands, United Kingdom; Radboud University Medical Center, Nijmegen, Netherlands; University of Umeå, Umeå, Sweden; University of Athens, Athens, Greece; Harbor UCLA Medical Center, Torrance, CA; Harvard Medical School Brigham and Women's Hospital, Boston, MA; Hospital Universitario Marques de Valdecilla, Santander, Spain; School of Physiology, Faculty of Health Sciences, Witwatersrand University, Johannesburg, South Africa; University of Manitoba, Winnipeg, MB, Canada; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubir, México City, Mexico; Hospital Medisch Spectrum Twente, Enschede, Netherlands
Background/Purpose Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease (CVD). CVD risk scores for the general population do not accurately predict…
Abstract Number: 842 • 2014 ACR/ARHP Annual Meeting
Is Rheumatoid Arthritis a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Jie Zhang¹, Shuo Yang², Lang Chen³, Fenglong Xie⁴, Huifeng Yun⁵, Paul M. Muntner⁶, Emily Levitan⁶, Monica Safford⁷, Kenneth G. Saag⁸, Jasvinder A. Singh⁷ and Jeffrey R. Curtis⁷, ¹Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Recently cholesterol treatment guidelines recommend that diabetes (DM) should be considered a CVD risk equivalent to a history of coronary heart disease (CHD). Despite…
Abstract Number: 341 • 2014 ACR/ARHP Annual Meeting
Death Receptor 3 Causes Vascular Dysfunction in a Murine Model of Rheumatoid Arthritis
Jessica O Williams¹, Eddie C.Y. Wang², Derek Lang¹ and Anwen S. Williams², ¹Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom, ²Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Increased cardiovascular (CV) risk is prevalent in several forms of inflammatory arthritides. The mechanisms that regulate CV disease during early inflammatory arthritis are ill-defined.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].